lybalvi

combination of Olanzapine and samidorphan

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

1.	Weight Gain 01/01/2022 - "Olanzapine-samidorphan combination tablets (OLZ/SAM), branded as Lybalvi, is a newly FDA approved formulation aimed at attenuating antipsychotic induced weight gain via modulation of the endogenous opioid system with samidorphan, while retaining the robust antipsychotic efficacy of olanzapine. "
2.	Schizophrenia (Dementia Praecox) 11/29/2021 - "Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder." 01/01/2022 - "A literature search of PubMed was performed (March 2006 to November 2021) using the following search terms: Lybalvi, olanzapine/samidorphan, olanzapine, antipsychotic, bipolar disorder, and schizophrenia. "
3.	Bipolar Disorder (Manic Depressive Psychosis) 11/29/2021 - "Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder." 01/01/2022 - "A literature search of PubMed was performed (March 2006 to November 2021) using the following search terms: Lybalvi, olanzapine/samidorphan, olanzapine, antipsychotic, bipolar disorder, and schizophrenia. "

1.	Olanzapine (Zyprexa)
2.	3-carboxamido-4-hydroxynaltrexone
3.	Antipsychotic Agents (Antipsychotics)
4.	Tablets
5.	Opioid Analgesics (Opioids)